Semaglutide
Prescription status is set country by country — the label where you live is the one that applies.
Beta: the medication section is still being tested, and its data may contain errors. Do not rely on it for a decision about your own treatment.
Semaglutide is a GLP-1 receptor agonist. It mimics the gut hormone GLP-1, increasing glucose-dependent insulin release, damping glucagon, slowing stomach emptying and reducing appetite. It is used in type 2 diabetes and in weight management.
A usual adult range, not a national label — the dose and the timing differ by country and by product.
Approved uses differ by country — some of these may be off-label or unapproved where you live.
Nausea, fullness and reflux are common at the beginning and usually settle; smaller, slower, less fatty meals help. Because appetite drops, protein intake needs deliberate attention so that muscle is not lost along with weight, while HbA1c, glucose and ALT are the tracked lab values. Delayed stomach emptying can change how other oral drugs are absorbed, and the risk of low blood sugar rises when it is combined with insulin or sulfonylureas; a personal or family history of medullary thyroid cancer is the reason for caution in thyroid disease.
Severe abdominal pain spreading to the back with vomiting can mean pancreatitis and needs prompt assessment. A lump in the neck, hoarseness or trouble swallowing, and vomiting that prevents drinking, are also reasons to see a doctor.
Reference information, not medical advice. Discuss any change with your doctor.